Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 plus pucotenlimab as neoadjuvant therapy for locally advanced oropharyngeal squamous cell carcinoma
ChiCTR2600131390Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of becotatug vedotin and pucotenlimab in oropharyngeal squamous cell carcinoma (OPSCC) (2 cohorts), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Major pathological response. Started May 2026; status: recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on ChiCTR2600131390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131390.